CYLD and Snail1 immunoreactivity in relation to clinico-pathological characteristics
| CYLD IHC | Snail1 IHC | |||||||||
| Variable | Categorization | n analyz. | neg. | weak pos. (score 1+) | strong pos. (score 2+) | Pa | n analyz. | neg. | pos. | Pa |
| Primary malignant melanomasb | ||||||||||
| Age at diagnosis | >60 yr | 48 | 25 | 16 | 7 | 0.647 | 43 | 16 | 26 | 1 |
| <60 yr | 40 | 23 | 14 | 3 | 36 | 13 | 23 | |||
| Gender | female | 39 | 20 | 15 | 4 | 0.745 | 34 | 16 | 18 | 0.157 |
| male | 49 | 28 | 15 | 6 | 44 | 13 | 31 | |||
| Clark level | II-III | 20 | 8 | 6 | 6 | 0.018 | 16 | 9 | 7 | 0.145 |
| IV-V | 67 | 39 | 24 | 4 | 61 | 20 | 41 | |||
| Tumor thickness | <1.75 mm | 22 | 11 | 5 | 6 | 0.027 | 17 | 10 | 7 | 0.049 |
| >1.75 mm | 66 | 37 | 25 | 4 | 61 | 19 | 42 | |||
| Growth pattern | NOS | 11 | 5 | 4 | 2 | 0.854 | 8 | 3 | 5 | 0.505 |
| SSM | 38 | 20 | 12 | 6 | 36 | 14 | 22 | |||
| ALM | 6 | 5 | 1 | 0 | 5 | 0 | 5 | |||
| NMM | 30 | 16 | 12 | 2 | 27 | 11 | 16 | |||
| LMM | 3 | 2 | 1 | 0 | 2 | 1 | 1 | |||
| CYLD IHC | Snail1 IHC | |||||||||
| Variable | Categorization | n analyz. | neg. | weak pos. (score 1+) | strong pos. (score 2+) | Pa | n analyz. | neg. | pos. | Pa |
| Primary malignant melanomasb | ||||||||||
| Age at diagnosis | >60 yr | 48 | 25 | 16 | 7 | 0.647 | 43 | 16 | 26 | 1 |
| <60 yr | 40 | 23 | 14 | 3 | 36 | 13 | 23 | |||
| Gender | female | 39 | 20 | 15 | 4 | 0.745 | 34 | 16 | 18 | 0.157 |
| male | 49 | 28 | 15 | 6 | 44 | 13 | 31 | |||
| Clark level | II-III | 20 | 8 | 6 | 6 | 0.018 | 16 | 9 | 7 | 0.145 |
| IV-V | 67 | 39 | 24 | 4 | 61 | 20 | 41 | |||
| Tumor thickness | <1.75 mm | 22 | 11 | 5 | 6 | 0.027 | 17 | 10 | 7 | 0.049 |
| >1.75 mm | 66 | 37 | 25 | 4 | 61 | 19 | 42 | |||
| Growth pattern | NOS | 11 | 5 | 4 | 2 | 0.854 | 8 | 3 | 5 | 0.505 |
| SSM | 38 | 20 | 12 | 6 | 36 | 14 | 22 | |||
| ALM | 6 | 5 | 1 | 0 | 5 | 0 | 5 | |||
| NMM | 30 | 16 | 12 | 2 | 27 | 11 | 16 | |||
| LMM | 3 | 2 | 1 | 0 | 2 | 1 | 1 | |||
CYLD and Snail1 immunohistochemical staining of primary malignant melanoma tissue was performed using a tissue microarray consisting of 88 cases. Investigation of CYLD protein expression was informative in all specimens, and immunohistochemical analysis of Snail1 was informative in 78 samples. NOS, not otherwise specified; SSM, superficial spreading melanoma; ALM, acral lentiginous melanoma; NMM, nodular malignant melanoma; LMM, lentigo malignant melanoma.
Fisher's exact test (two-sided). Significant data are shown is bold.
Only initial and unifocal malignant melanomas were included.